Lipicard Technologies Limited – Product Pipeline Review

Global Markets Direct’s, ‘Lipicard Technologies Limited – Product Pipeline Review – 2016’, provides an overview of the Lipicard Technologies Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Lipicard Technologies Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Lipicard Technologies Limited

The report provides overview of Lipicard Technologies Limited including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Lipicard Technologies Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Lipicard Technologies Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Lipicard Technologies Limited’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Lipicard Technologies Limited

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Lipicard Technologies Limited’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Lipicard Technologies Limited Snapshot 7

Lipicard Technologies Limited Overview 7

Key Information 7

Key Facts 7

Lipicard Technologies Limited - Research and Development Overview 8

Key Therapeutic Areas 8

Lipicard Technologies Limited - Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products - Monotherapy 12

Lipicard Technologies Limited - Pipeline Products Glance 13

Lipicard Technologies Limited - Early Stage Pipeline Products 13

Preclinical Products/Combination Treatment Modalities 13

Discovery Products/Combination Treatment Modalities 15

Lipicard Technologies Limited - Drug Profiles 16

gabafol 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

KeraKlear 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

LT-1121 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

LT-1123 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

LT-2121 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

LT-2221 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

LT-2223 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

LT-2321 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

LT-2322 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

LT-2323 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

LT-2421 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

LT-2423 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

LT-2521 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

LT-3121 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

LT-3122 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

LT-4121 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

LT-4122 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

LT-4123 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

LT-4124 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

LT-4125 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

LT-4126 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

LT-5121 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

LT-5122 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

LT-5221 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

LT-5222 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

LT-5223 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

LT-5321 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

LT-5322 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

LT-5323 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

LT-5421 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

LT-5423 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

LT-5521 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

peroxibrate 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

platrol 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

raviprofen 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

LT-6121 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Lipicard Technologies Limited - Pipeline Analysis 52

Lipicard Technologies Limited - Pipeline Products by Target 52

Lipicard Technologies Limited - Pipeline Products by Route of Administration 53

Lipicard Technologies Limited - Pipeline Products by Molecule Type 54

Lipicard Technologies Limited - Pipeline Products by Mechanism of Action 55

Lipicard Technologies Limited - Locations And Subsidiaries 56

Head Office 56

Appendix 57

Methodology 57

Coverage 57

Secondary Research 57

Primary Research 57

Expert Panel Validation 57

Contact Us 57

Disclaimer 58

List of Tables

List of Tables

Lipicard Technologies Limited, Key Information 7

Lipicard Technologies Limited, Key Facts 7

Lipicard Technologies Limited – Pipeline by Indication, 2016 9

Lipicard Technologies Limited – Pipeline by Stage of Development, 2016 11

Lipicard Technologies Limited – Monotherapy Products in Pipeline, 2016 12

Lipicard Technologies Limited – Preclinical, 2016 13

Lipicard Technologies Limited – Discovery, 2016 15

Lipicard Technologies Limited – Pipeline by Target, 2016 52

Lipicard Technologies Limited – Pipeline by Route of Administration, 2016 53

Lipicard Technologies Limited – Pipeline by Molecule Type, 2016 54

Lipicard Technologies Limited – Pipeline Products by Mechanism of Action, 2016 55

List of Figures

List of Figures

Lipicard Technologies Limited – Pipeline by Top 10 Indication, 2016 9

Lipicard Technologies Limited – Pipeline by Stage of Development, 2016 11

Lipicard Technologies Limited – Monotherapy Products in Pipeline, 2016 12

Lipicard Technologies Limited – Pipeline by Target, 2016 52

Lipicard Technologies Limited – Pipeline by Route of Administration, 2016 53

Lipicard Technologies Limited – Pipeline by Molecule Type, 2016 54

Lipicard Technologies Limited – Pipeline Products by Mechanism of Action, 2016 55

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared